겸상 적혈구 빈혈 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Sickle Cell Anemia Market size is expected to reach USD 13.16 Billion in 2034 from USD 9.90 Billion (2025) growing at a CAGR of 3.22% during 2026-2034.

The global sickle cell anemia market is gaining attention due to increasing awareness and advancements in the treatment of genetic blood disorders. Sickle cell anemia is an inherited condition that affects the shape and function of red blood cells, leading to severe pain episodes and other complications. Rising prevalence in certain regions and increasing screening programs are driving the demand for effective treatment solutions.

Advancements in medical research and drug development are major factors supporting the growth of the sickle cell anemia market. Innovative therapies such as gene therapy, bone marrow transplantation, and new disease-modifying drugs are improving treatment outcomes for patients. Governments and healthcare organizations are also promoting early diagnosis and management programs to reduce disease complications.

In the future, the sickle cell anemia market is expected to witness substantial growth due to ongoing research in genetic therapies and personalized medicine. Breakthrough treatments aimed at correcting the underlying genetic defect offer promising long-term solutions. Increasing global focus on rare disease treatment and improved healthcare access will continue to support market development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy types

• Bone Marrow Transplants
• Medications
• Blood Transfusions
• Gene Therapy

By Distribution channels

• Clinics
• Hospitals
• Home Healthcare

COMPANIES PROFILED

• Bluebird Bio, Eli Lilly, Gilead Sciences, Inc, Merck Co, Inc, Novartis AG, Sanofi, Baxter, BristolMyers Squibb Company, Global Blood Therapeutics, Johnson Johnson, Mast Therapeutics, Pfizer, Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SICKLE CELL ANEMIA MARKET: BY THERAPY TYPES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Types
• 4.2. Bone Marrow Transplants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Blood Transfusions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SICKLE CELL ANEMIA MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channels
• 5.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Home Healthcare Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SICKLE CELL ANEMIA MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Therapy Types
  • 6.2.2 By Distribution Channels
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Therapy Types
  • 6.3.2 By Distribution Channels
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Therapy Types
  • 6.4.2 By Distribution Channels
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Therapy Types
  • 6.5.2 By Distribution Channels
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Therapy Types
  • 6.6.2 By Distribution Channels
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SICKLE CELL ANEMIA INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Bluebird Bio
  • 8.2.2 Eli Lilly
  • 8.2.3 Gilead SciencesInc
  • 8.2.4 Merck & Co.Inc
  • 8.2.5 Novartis AG
  • 8.2.6 Sanofi
  • 8.2.7 Baxter
  • 8.2.8 Bristol-Myers Squibb Company
  • 8.2.9 Global Blood Therapeutics
  • 8.2.10 Johnson & Johnson
  • 8.2.11 Mast Therapeutics
  • 8.2.12 PfizerInc